Drugs / B1962
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05650385 | Dec 2022 → Dec 2023 | cancer | Tasly Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06838546 | Feb 2025 → Jan 2027 expected | colorectal cancer | Tasly Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06724263 | Dec 2024 → Aug 2026 overdue | cervical cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung carcinoma +2 | Tasly Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B1962 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06838546 ↗ |
| Action | Inhibit | “B1962 has higher VEGF anti angiogenic activity than its competitors.” NCT06724263 ↗ |
| Modality | Protein / enzyme biologic | “B1962 is a PD-L1/VEGF bispecific antibody fusion protein.” NCT05650385 ↗ |
| Route | Intravenous | “B1962 35 mg/kg, intravenous infusion” NCT06838546 ↗ |